SANUWAVE HealthSNWV
Recorded

SANUWAVE Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration27 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome everyone joining today's Sanuwave earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note, this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Morgan Frank, Chairman and CEO of Sanuwave. Please go ahead. Thank you very much.

Morgan FrankChairman and CEO

Good morning, and welcome to Sanuwave's third quarter 2026 earnings call. As ever, our Form 10-Q was filed with the SEC last night, along with our earnings release, and our updated presentation was made available on our website in the investor section. Please refer to that during the presentation. Joining me on this call is Peter Sorensen, our CFO, and after the presentation, we will open the call to Q&A. Let me begin with the always popular forward-looking statements and other disclosures. This call may contain forward-looking statements, such as statements relating to future financial results, production expectations, plans for future business development activities, and expectations regarding the impact of changes in reimbursement levels and tariff rates on the company and its industry.

Morgan FrankChairman and CEO

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. A description of these risks and uncertainties and other factors that could affect our financial results is included in our SEC filings. Actual results may differ materially from those projected in the forward-looking statements. The company undertakes no obligation to update any forward-looking statement. Certain percentages discussed in this call are calculated from the underlying whole dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes. As a reminder, our discussion today will include non-GAAP numbers. Reconciliations between our GAAP and non-GAAP results can be found on our recently filed 10-Q for the period ended September 30, 2026. Okay, Q3 was really the story of the CMS proposed rule.

Morgan FrankChairman and CEO

As this came out on July 14, it affected most of the quarter, and its effects were profound. Two issues in the proposed rule had a large impact on Sanuwave. The first was the choice by CMS not to increase the price for skin substitute reimbursement for 2027. Obviously, as we've discussed in the past, this is not a product area in which we participate, but it's a modality that has been used by a great many wound care companies, including a number of our customers. Many in the industry seemed to have been expecting an increase in the price per square centimeter and were holding on in their business in hopes of a return to higher rates.

Morgan FrankChairman and CEO

Many, particularly in mobile wound care, especially in rural, were operating at losses, but were seeking to keep their patient, practitioner, and account bases intact in hopes of this return to higher pricing. Without that increase in rates for 2027, we saw a sort of last shoe to drop series of exits from the business as folks seemed to decide that any eventual oasis that might emerge was just simply too far away. This affected our customer base. We saw some significant accounts shut their doors or eliminate portions of their business, reducing staff and scope. Much of this occurred early in the quarter, and so those effects were present for most of Q3. This was somewhat offset by the addition of new customers and an increase at some other existing customers who seemed to be expanding into some of the empty space and accounts left by those exiting.

Morgan FrankChairman and CEO

As we've discussed in the past, the patients and wounds didn't go away, and someone will need to treat them, but of course, such transitions are messy and they take time. While still representing our second-highest quarterly total ever, behind only Q2 of this year, overall, our applicator revenue declined approximately 4% in Q3 as compared to Q2.

Morgan FrankChairman and CEO

Larger revenue variance occurred on the capital equipment side, where systems sold in the quarter dropped from 82 in Q2 to 40 in Q3, as ongoing used systems in the market as a result of former customers closing their doors continued to cannibalize sales, as well as from a great deal of the market taking a sort of wait-and-see approach to buying UltraMIST systems in response to the second aspect of the CMS rule which affected Sanuwave, the proposed reduction in the reimbursement rate for 97610 based upon the nomination of that code as mispriced. This confluence of events led to some odd-looking outcomes, such as the company adding 60 new customers in the quarter, while despite selling only 40 systems.

Morgan FrankChairman and CEO

Customers exiting, reducing practitioner counts, and acquiring used systems have frankly made a bit of a mess of the active systems number that we have traditionally reported, and we're simply not confident that it has the resolution to be worth sharing right now. The overall active customer count, which we measure by invoices, took a hit in July from which we made up some ground as the rest of the quarter went on. The full number of customers who placed orders in Q3 was about 2% higher than in Q2. As many of you likely saw, we and many others submitted comments to CMS regarding this proposed change, and we're extremely grateful to those who did.

Morgan FrankChairman and CEO

In the end, CMS chose to implement the rule as drafted with some minor changes, such as increasing the kit price, which is a subset component of the overall price, to $125 from $100, and the inclusion of sales tax expense. There seems to be some confusion about what this actually means. For the sake of clarity, our calculations based upon the RVU figures and the published conversion factor that is applied to all CMS payments, we are estimating that the physician fee schedule payment for 97610 in 2027 will be $314.54, down from $397.81 in 2026. For more detail on this and on other aspects of the proposed rule, including expected impact for 2028, you can see our press release from November 5th.

Morgan FrankChairman and CEO

This was not the news we were hoping for, but the news was also not all bad, and there were some silver linings in amongst the rain clouds. Firstly, the hospital outpatient rate for 2027 increased approximately 14% from 2026, rising to $235.04 from $204.98. Perhaps more consequentially, the 97610 code had its Q1 status indicator removed and replaced with a T. For those who do not speak reimbursement, which I am presuming is most people, that means that the code will go from being paid only when no other separately billable or separately payable procedure appears on the same claim for the same day, whereas Q1 would package our code in such a circumstance and pay it zero, to being billable with other codes. That is actually a big deal.

Morgan FrankChairman and CEO

More than half of 97610 HOPD treatments in 2025 were packaged and paid at zero, and we suspect that that figure significantly undercounts this overall issue, as incentives to bother billing at all are low when you know it is going to be packaged. We look forward to getting this additional billing information, as we suspect that the instances that got zeroed were the ones with more complex and more expensive wounds, and the emergence of this fact in the data will help us make the case that our code belongs in a higher APC group with higher reimbursement rates. The other interesting silver lining came in the comment from the AMA RUC and its CMS response to it within the Federal Register.

Morgan FrankChairman and CEO

For those not familiar, the RUC is an expert multi-specialty panel managed by the American Medical Association that makes recommendations to the federal government regarding relative value units for medical procedures. They weighed in and requested that, and I am going to quote here to avoid putting words in other people's mouths, that, and we quote, "CMS delay finalization of changes to CPT code 97610 pending RUC review process." This is very much what we were hoping for as well. Obviously, in the event, CMS did not delay finalization, but they did, however, make a specific statement that we found very interesting, and again, I am going to quote here.

Morgan FrankChairman and CEO

In the event that there is a new RUC review of this service, we would look forward to receiving any additional information, invoices, or new data about the broader coding structure, specifically regarding depth, size, wound quantity, or anatomic site distinctions and same-day billing restrictions. That is quite a specific list, and interestingly enough, it is one that aligns very closely with many of our asks in our CMS comment. Compared to most other wound codes, 97610 is unusual in that it contains no scaling factors for number of wounds, their size, their difficulty, their site. It also subsumes other codes if multiple treatments occur at the same time and winds up having to cover the whole of the episode of care.

Morgan FrankChairman and CEO

I know many have asked, "Why is CMS trying to wipe out your code?" But honestly, having seen these responses, we are not seeing, strange as it sounds, we are not seeing it that way. This actually seems like an invitation to help restructure this code into something that is better aligned with the reality of use cases, especially around large wounds and our patients with multiple wounds. The average wound care patient has 2.4 wounds. Our hope is to work with both the RUC and with CMS on this and to find a code structure that works for patients, physicians, and for payers alike. In the meantime, we are continuing to rack up some wins in a number of applications and user bases in which cost containment and reduction of inpatient length of stay and recidivism are the key metrics. HAPI, hospital-acquired pressure injury, presents an excellent example.

Morgan FrankChairman and CEO

This is a $27 billion market, and the cost of such wounds rise rapidly with severity. Estimates we have seen from ICU show that the difference in incremental cost, and this is translated to 2025 dollars, per patient per stay rise from $40,000 of additional costs for a stage 2 partial thickness HAPI to $69,000 for stage 3, which is full thickness with visible subcutaneous fat, and then up to $113,000 for a stage 4 wound that has gotten through the fat and now has visible muscle, tendon, or bone. Unstageable wounds can get worse still. Keeping one wound from moving from stage 2 to stage 4 will save over $70,000 across a patient hospitalization. We see large opportunities here. It is one of the things we have restructured our sales force around, and we have been increasingly focused on this market over the last 12 to 18 months.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day